VCBeat Health Contact Us
Home Aumolertinib-Based Targeted Therapy Achieves Intracranial and Extracranial Partial Response Within Four Cycles in EGFR-Mutant NSCLC with TP53 Co-Mutation and Brain Metastases

Aumolertinib-Based Targeted Therapy Achieves Intracranial and Extracranial Partial Response Within Four Cycles in EGFR-Mutant NSCLC with TP53 Co-Mutation and Brain Metastases

Jun 09, 2026 20:20 CST Updated 20:20
Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Image
Image
Image
Image
Image
Image
Image



✩ This article is intended for reference by healthcare professionals only.




Approval No.: HS-NP-A505A-2606-01505

Disclaimer: This article is intended solely for reference by healthcare professionals and is not for advertising purposes. Hansoh Pharma does not recommend the use of any unapproved drugs and/or drugs for unapproved indications, nor does it make any recommendations regarding any drugs and/or indications. The information contained herein is for reference only; please follow the advice or guidance of physicians or other healthcare professionals.


Content Planning: Fang Cheng

Project Review: Yin Zhihui


References:

[1]Wang J, Wang Z J, Zhong J, et al. PL02. 09 Aumolertinib plus Chemotherapy for NSCLC with EGFR and Concomitant Tumor Suppressor Genes (ACROSS 2): Phase III study[J]. Journal of Thoracic Oncology, 2025, 20(10): S1-S2.

[2]Duan JC, Zhong J, Sun BY, et al. Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. CA Cancer J Clin. 2026 Mar-Apr;76(2):e70071

[3]Lu S, Hu J, Chen J, et al. Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2). Cancer Res. 2025;85(8 Suppl 2):Abstract CT053. Presented at: AACR Annual Meeting 2025; April 25–30, 2025; Chicago, IL, USA.

[4]Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Annals of Oncology, 2019, 30(8): 1321-1328.

[5]Schoenfeld A J, Arbour K C, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib[J]. Annals of Oncology, 2019, 30(5): 839-844.

[6]Owen DH, Jaiyesimi IA, Leighl NB, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights. JCO Oncol Pract. 2024;20(7):893-898.

[7]Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Annals of Oncology, 2019, 30(8): 1321-1328.

[8]Schoenfeld A J, Arbour K C, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L) 1 blockade and osimertinib[J]. Annals of Oncology, 2019, 30(5): 839-844.

[9]Owen DH, Jaiyesimi IA, Leighl NB, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights. JCO Oncol Pract. 2024;20(7):893-898.

[10]Sun F, Banwait M K, Singhal S, et al. Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer[J]. Lung Cancer, 2025: 108747.

[11]Ma J, Pang X, Zhang S, et al. First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis[J]. Scientific Reports, 2024, 14(1): 22901.

[12]D. Planchard, et al. Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2. 2025 ELCC 53P. Journal of Thoracic Oncology (2025) 20 (3): S1-S97.0.


Image